Tempus AI

Tempus AI is a healthcare technology company that uses artificial intelligence, clinical data, genomic testing, and advanced analytics to support precision medicine. Founded in 2015 by Eric Lefkofsky, the company develops technology and diagnostic services for healthcare providers, hospitals, research institutions, pharmaceutical companies, biotechnology organisations, and patients. Its work focuses on connecting molecular information with clinical records and medical imaging to help healthcare professionals make more informed decisions about diagnosis, treatment selection, and patient care.

The company was established with the goal of making healthcare data more useful in clinical practice. Medical records, genomic test results, pathology images, radiology scans, and treatment histories can contain valuable information, but these records are often stored in different systems and formats. Tempus brings together different types of health information and applies computational methods to help identify patterns that may be relevant to patient care and medical research. Its technology supports both clinical applications and pharmaceutical research, creating a connection between information collected during healthcare delivery and discoveries that may improve future treatments.

Tempus describes its approach as AI-enabled precision medicine. Rather than treating every patient with the same diagnosis as having identical treatment needs, precision medicine considers individual characteristics such as genetic alterations, molecular biomarkers, medical history, and other clinical information. Tempus uses this information to develop diagnostic tests, clinical decision-support applications, research datasets, and AI models that can help clinicians and researchers investigate disease and treatment response.

Oncology is one of the company’s largest areas of activity. Tempus offers a portfolio of genomic and molecular diagnostic tests designed to help clinicians understand the biological characteristics of cancer. These tests can identify genetic alterations and biomarkers that may be relevant to treatment selection, hereditary cancer risk, clinical trial eligibility, and disease monitoring. Its oncology testing portfolio includes DNA sequencing, RNA sequencing, whole-exome analysis, and other specialised biomarker tests.

One of its major diagnostic offerings is the xT test, a comprehensive genomic profiling test for solid tumours and certain haematological cancers. It analyses tumour DNA to identify genomic alterations that may help clinicians understand the molecular characteristics of a patient’s cancer. The company also offers xT CDx, an FDA-approved companion diagnostic designed to identify biomarkers associated with specific treatment decisions. These tests can provide information that clinicians may use alongside pathology findings, medical history, and established clinical guidelines.

Tempus also provides xR, a whole-transcriptome RNA sequencing test. RNA analysis can provide additional information about gene expression and molecular activity that may not be fully captured by DNA testing alone. By combining DNA and RNA information, healthcare professionals may obtain a broader view of a tumour’s molecular profile. Other testing options include xF and xF+, which use circulating tumour DNA analysis, and xE, which provides whole-exome DNA sequencing. The appropriate test depends on the patient’s clinical situation and the healthcare professional’s testing requirements.

Another important part of its oncology portfolio is hereditary cancer testing. Through its acquisition of Ambry Genetics, Tempus provides inherited genetic testing services that help assess whether a person may carry genetic variants associated with an increased risk of certain cancers or other inherited conditions. Its hereditary testing portfolio includes CancerNext, CancerNext-Expanded, BRCAplus, and other specialised panels. These tests can help clinicians investigate inherited cancer risk and determine whether additional screening, counselling, or family risk assessment may be appropriate.

Tempus also offers molecular residual disease and treatment-response monitoring solutions. Its xM test is designed to detect circulating tumour DNA and support monitoring after cancer treatment. The company also offers xM (NeXT Personal Dx), a tumour-informed test that uses information from an individual’s tumour to monitor for molecular evidence of residual disease. These technologies are intended to provide additional information that clinicians can consider when monitoring patients, evaluating treatment response, and planning follow-up care. Results must be interpreted within the relevant clinical context and are not a substitute for other required medical assessments.

Beyond cancer diagnostics, Tempus has expanded into cardiology. Its cardiovascular solutions use AI and clinical information to help identify patients who may have undiagnosed or undertreated heart conditions. One of its products is ECG-AI, a collection of algorithms designed to analyse electrocardiogram recordings and identify signals associated with particular cardiovascular conditions. The technology can help clinicians identify patients who may benefit from further evaluation. Tempus has also developed FDA-cleared ECG-related software products, including solutions for identifying signs associated with atrial fibrillation, reduced ejection fraction, and pulmonary hypertension. These tools are intended to support clinical assessment rather than independently establish a complete diagnosis.

Tempus also operates in radiology through its Pixel platform. Pixel provides AI-assisted medical imaging tools that help radiologists and other healthcare professionals analyse scans, quantify findings, and prepare reports. Its capabilities include automated lesion segmentation, measurement, longitudinal tracking, and reporting. These functions can help clinicians compare imaging findings across different examinations and monitor changes over time. Pixel also supports specialised cardiac magnetic resonance imaging workflows, including image visualisation and quantitative analysis. Its imaging applications are designed to work within existing clinical environments rather than requiring radiologists to abandon their established systems.

Another major component of the company’s technology ecosystem is Tempus Hub. Hub is a digital platform designed for healthcare providers who order Tempus tests and need to access patient information and results. It allows authorised users to place diagnostic orders, monitor order status, review test reports, and access relevant patient information. The platform combines molecular and clinical findings to make important information easier to review. It can also present biomarker results, potential treatment information, and relevant clinical trial opportunities.

Tempus Hub includes Tempus One, an AI-enabled clinical assistant that helps healthcare professionals access patient and treatment information. Clinicians can interact with the assistant through written questions or voice-based requests, depending on the available implementation. It can help retrieve information about patient histories, test reports, actionable biomarkers, treatment options, and clinical trials. Its EHR-connected capabilities also support tasks such as summarising medical records, preparing clinical documentation, and accessing information from existing patient records. These functions are intended to assist healthcare professionals with information retrieval and administrative work, while clinical decisions remain the responsibility of qualified practitioners.

Tempus Next is another product within the company’s healthcare platform. It is designed to help healthcare organisations identify patients who may have gaps in recommended care and support the delivery of guideline-based treatment pathways. In oncology, the platform can help identify patients who may be eligible for particular tests, therapies, or clinical trials. Its cardiology applications help clinicians identify patients who may have undertreated cardiovascular conditions. The system can also provide dashboards for tracking care gaps, clinical pathways, and follow-up activities across a patient population.

The company has also developed Tempus Lens, an AI-powered data and research platform for pharmaceutical companies, biotechnology organisations, and scientific researchers. Lens provides access to de-identified real-world patient information and multimodal datasets that can include clinical records, molecular profiles, pathology images, radiology information, and treatment outcomes. Researchers can use these resources to investigate disease patterns, identify potential biomarkers, build patient cohorts, evaluate treatment outcomes, and support clinical trial planning.

Lens combines access to research data with analytical tools and AI models. It is designed to help research teams investigate complex questions without having to manually review every individual record. Its workflows can support cohort identification, clinical trial feasibility analysis, biomarker research, and the evaluation of real-world treatment outcomes. Researchers can also use the platform to work with their own datasets in combination with Tempus resources, subject to the relevant agreements and data-access permissions.

Tempus One is also available within the research environment. In this setting, it can help researchers explore patient populations, query clinical information, and generate summaries from supported datasets. Its agent-based capabilities are intended to assist with scientific workflows, allowing research teams to move from a research question to structured analysis more efficiently. Tempus Lens is therefore relevant to pharmaceutical research and drug development as well as the company’s clinical healthcare activities.

Foundation models are another important part of Tempus’ technology strategy. The company develops AI models using multimodal medical information to investigate relationships between molecular characteristics, pathology images, clinical records, and patient outcomes. Its model portfolio includes Virchow, a computational pathology foundation model, PRISM, a model for pathology-related applications, and oFM, an oncology foundation model designed to combine different types of patient information. These models are intended to support research, biomarker discovery, and the development of additional AI applications. Models must undergo appropriate validation and obtain any required regulatory authorisation before being used for clinical purposes.

Tempus also provides data and AI services to pharmaceutical and biotechnology companies. These services can support different stages of drug development, including target identification, biomarker strategy, clinical trial design, patient recruitment, and the evaluation of treatment outcomes. Its real-world data resources can help researchers understand how treatments perform in broader patient populations and investigate whether particular groups may respond differently to a therapy. The company also offers research collaborations and access to selected datasets and analytical capabilities.

Clinical trial matching is another important application of the platform. Tempus uses patient information, molecular findings, and clinical criteria to help identify individuals who may meet the requirements for particular research studies. Its systems can support healthcare providers and research organisations by identifying potentially eligible patients and helping research teams assess trial feasibility. The technology can also support clinical trial recruitment workflows through Tempus Next and related research services. Final eligibility decisions remain subject to the study protocol and the research team’s review.

Integration with healthcare systems is central to Tempus’ operations. The company connects its technology with electronic health record systems and other clinical applications to help healthcare providers access information within their existing workflows. Its integrations include major healthcare platforms such as Epic, Oracle Health’s Cerner systems, MEDITECH, Flatiron OncoEMR, IKnowMed, and Veradigm. Tempus also supports connections with radiology and imaging environments through systems such as picture archiving and communication systems, or PACS. Its investor materials report thousands of healthcare integrations across its network.

Tempus also offers Olivia, a patient-focused health application that helps users organise and understand their health information. The application can connect with participating healthcare systems, collect medical records, and present information such as laboratory results, imaging reports, visit summaries, medications, and medical history in one place. Its AI features can help users summarise their records and ask questions about information contained in their health data. Olivia also supports health-monitoring connections with services such as Apple Health and Google Fit. It is designed to help patients manage and understand their information, not to replace professional medical care.

Privacy, security, and responsible handling of medical information are important considerations across Tempus’ services. The company works with sensitive clinical and molecular data and describes processes for de-identification, data governance, and secure access. Its platforms are intended for use within healthcare and research environments where permissions, regulatory requirements, and data-protection obligations must be considered. Organisations evaluating Tempus should review the applicable privacy, security, and contractual requirements for the particular product and deployment.

Tempus is primarily a healthcare technology and diagnostics company rather than a general-purpose AI application. Its solutions are designed for medical professionals, hospitals, research organisations, pharmaceutical companies, and patients using its supported services. Some products are available through healthcare providers or enterprise partnerships, while diagnostic testing is generally ordered through qualified medical professionals. The company does not offer one universal self-service subscription covering its entire platform.

The range of products makes Tempus relevant across oncology, cardiology, radiology, clinical research, and pharmaceutical development. Its combination of diagnostic testing, multimodal data, AI models, clinical software, and research services gives it a broader role than a standalone medical imaging or genomic testing provider. Its technology is most useful when integrated into established clinical and research workflows, with appropriate professional oversight and validation.

Pricing

Tempus AI does not publish a universal public subscription price for its diagnostic tests, clinical platforms, research datasets, or enterprise AI services. Costs depend on the product, testing requirements, healthcare provider, payer arrangements, data licence, and implementation agreement.

• Genomic and molecular diagnostic testing – Variable pricing: Tests such as xT, xT CDx, xR, xF, xE, hereditary panels, and MRD testing are generally ordered through healthcare professionals. Payment may involve insurance reimbursement, healthcare providers, pharmaceutical partners, or direct patient billing, depending on the test and circumstances.
• Tempus Hub – Contact for pricing: Access is arranged for healthcare providers and participating organisations.
• Tempus One – Contact for pricing: Availability is connected to Tempus Hub, EHR access, and relevant provider or research arrangements.
• Tempus Next – Contact for pricing: Pricing depends on the healthcare organisation and selected care-pathway solutions.
• Tempus Pixel – Contact for pricing: Imaging software and related services are offered through healthcare organisation agreements.
• Tempus Lens – Contact for pricing: Research data, AI models, analytics, and platform access are arranged through commercial partnerships and licensing agreements.
• Olivia – Free consumer application: The patient-facing application is available as a separate service, with access and features subject to its current terms.

Patients should confirm potential out-of-pocket costs, insurance coverage, and reimbursement requirements with their healthcare provider and insurer before undergoing diagnostic testing.

Review

Tempus AI is a significant healthcare technology platform because it combines diagnostic testing, clinical information, medical imaging, genomic data, and artificial intelligence. Its main strength is the way it connects different types of medical information to support precision medicine. This makes it relevant to healthcare providers who need more detailed molecular insights, as well as researchers and pharmaceutical companies working on new treatments.

Its oncology portfolio is particularly extensive. The availability of DNA sequencing, RNA sequencing, hereditary testing, and molecular residual disease monitoring gives clinicians access to different types of information throughout the cancer-care journey. The company’s expansion into cardiology and radiology also demonstrates that its technology is not limited to genomic testing.

Tempus Hub and Tempus One provide useful clinical workflow capabilities. They help healthcare professionals access reports, review patient information, and retrieve relevant treatment and clinical trial insights. Tempus Next adds care-pathway support, while Pixel offers AI-assisted imaging analysis. These products make the platform relevant to hospitals and healthcare networks that want to incorporate data-driven tools into existing clinical operations.

Tempus Lens is another major advantage for research organisations. Its multimodal datasets and analytical tools can support cohort identification, biomarker research, clinical trial planning, and drug development. The foundation-model programme also provides opportunities for developing specialised AI applications using medical information and imaging data.

The company’s established healthcare integrations are valuable because clinical technology must fit into existing systems. Connections with major EHR platforms and imaging environments can help reduce the need for healthcare professionals to switch between unrelated applications. Its patient-focused Olivia application also adds a way for individuals to organise their medical information.

However, Tempus is not an inexpensive self-service AI tool with transparent monthly subscription plans. Many of its services are sold through healthcare contracts, diagnostic testing arrangements, data licensing, and enterprise partnerships. This makes it difficult for smaller organisations to estimate costs without contacting the company or reviewing the relevant billing arrangements.

Another limitation is that the platform covers several specialised areas, each with different technical and clinical requirements. Implementing its diagnostic services, EHR integrations, imaging tools, and research platform may require specialist staff and coordination. Organisations must also assess whether a particular test or AI feature is appropriate for their patient population and clinical workflow.

AI-generated insights and diagnostic results also require appropriate interpretation. A genomic finding, imaging analysis, or algorithmic output should not be treated as an independent medical decision. Healthcare professionals must consider the patient’s full clinical situation, applicable guidelines, and the regulatory status of the specific product. Some models are intended for research and require further validation before clinical use.

Overall, Tempus AI is a strong option for healthcare providers, research institutions, and pharmaceutical organisations seeking data-driven precision medicine capabilities. Its combination of molecular diagnostics, clinical AI, imaging analysis, real-world data, and research tools makes it a comprehensive healthcare technology company. Its enterprise-oriented pricing and specialised implementation requirements may limit accessibility for smaller organisations, but its broad product ecosystem offers substantial capabilities for established healthcare and life-sciences operations.